Robertson Stephens Wealth Management LLC Makes New $491,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Robertson Stephens Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 647 shares of the biopharmaceutical company’s stock, valued at approximately $491,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. State Street Corp lifted its stake in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE grew its position in Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after buying an additional 32,158 shares in the last quarter. Amundi grew its position in Regeneron Pharmaceuticals by 27.5% during the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after buying an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $807.48 on Wednesday. The company has a 50-day moving average of $791.41 and a 200-day moving average of $721.87. The company has a market capitalization of $83.14 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.35 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $572.75 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 47.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. Sanford C. Bernstein boosted their price target on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research note on Friday, August 14th. Truist Financial raised their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Robert W. Baird raised their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Piper Sandler lifted their price objective on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $845.59.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 in the last three months. 6.97% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.